| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | |
|---|---|---|---|---|---|---|
Operating Activities: | ||||||
Net (Loss) Income | ||||||
-7,096 | -10,811 | -13,217 | - | - | - | |
Net Loss | ||||||
- | - | - | -13,343 | -8,387 | -1,551 | |
Adjustments to Reconcile Net (Loss) Income to Net Cash Used in Operating Activities: | ||||||
Depreciation and Amortization of Intangible Assets | ||||||
51 | 38 | 19 | 5 | 1 | 1 | |
Reduction of Right-of-Use Assets | ||||||
162 | - | - | - | - | - | |
Non-Cash Interest Expense Charge on Beneficial Conversion Feature of Notes | ||||||
- | - | - | - | -1,663 | 0 | |
Non-Cash Interest Expense Related to Debt Discount | ||||||
- | - | - | - | 244 | 226 | |
Stock-Based Compensation | ||||||
852 | 875 | 870 | 510 | 1,224 | 26 | |
Contingent Consideration | ||||||
500 | - | - | - | - | - | |
Fair Value Adjustment on Common Stock Warrants | ||||||
- | - | - | - | -223 | -1,095 | |
Loss on cancellation of shareholders note receivable and related accrued interest receivable | ||||||
- | - | - | - | - | -200 | |
Extinguishment of research liability | ||||||
- | - | - | - | - | 240 | |
Loss on Cancellation of Stockholder Note Receivable | ||||||
- | - | -91 | 0 | - | - | |
Deferred Taxes | ||||||
95 | 86 | -1,341 | 0 | - | - | |
Changes in Operating Assets and Liabilities: | ||||||
License and Grant Receivable | ||||||
- | - | -37 | -3,233 | 907 | - | |
Accounts receivable | ||||||
- | - | - | - | - | 0 | |
Prepaid Expenses and Other Current Assets | ||||||
3 | -379 | 447 | -26 | 95 | 4 | |
Refundable Tax Credit Receivable | ||||||
-13 | -4 | 4 | -7 | 2 | -7 | |
Other Assets | ||||||
37 | -69 | 1 | 16 | 1 | 1 | |
Security deposit | ||||||
- | - | - | - | - | 30 | |
Accounts Payable | ||||||
146 | -642 | -706 | 712 | -148 | 552 | |
Lease Liabilities | ||||||
162 | - | - | - | - | - | |
Deferred Revenue | ||||||
-2,686 | 540 | 8,088 | - | - | - | |
Unbilled Revenue | ||||||
- | 689 | 0 | - | - | - | |
Deferred Revenue | ||||||
- | - | - | 0 | 1,907 | 0 | |
Accrued Expenses | ||||||
10 | -694 | 144 | 450 | 265 | 896 | |
Net Cash Used in Operating Activities | ||||||
-8,153 | -10,844 | -6,468 | -8,413 | - | - | |
Investing Activities: | ||||||
Restricted Cash | ||||||
- | - | - | - | 20 | 0 | |
Net Cash Used in Operating Activities | ||||||
- | - | - | - | -4,459 | -950 | |
Equipment Purchased Under Capital Lease | ||||||
- | - | - | 11 | 0 | - | |
Purchase of Property and Equipment | ||||||
- | 20 | 36 | 0 | - | - | |
Payment Under License Agreement | ||||||
- | 250 | 0 | - | - | - | |
Acquisition of Jade (Net of Cash Acquired) | ||||||
- | - | - | 185 | 0 | - | |
Net Cash Used in Investing Activities | ||||||
- | -270 | -36 | 174 | - | - | |
Financing Activities: | ||||||
Net Cash Provided by Investing Activities | ||||||
- | - | - | - | -20 | 0 | |
Proceeds from Initial Public Stock Offering | ||||||
- | - | - | - | - | 0 | |
Proceeds from Stock Offerings, Net of Offering Costs | ||||||
1,777 | 10,108 | 10,589 | 3,768 | 14,101 | - | |
Proceeds from convertible notes payable | ||||||
- | - | - | - | - | 1,755 | |
Exercise of Common Stock Options | ||||||
- | - | 40 | 56 | 26 | 6 | |
Exercise of Warrants | ||||||
2,150 | 1,205 | 0 | - | - | - | |
Proceeds from Employee Stock Purchase Plan | ||||||
- | - | 54 | - | - | - | |
Stock Issuance Costs | ||||||
- | - | - | 323 | - | - | |
Settlement of Fractional Shares | ||||||
2 | - | - | - | - | - | |
Offering Costs | ||||||
- | - | - | - | 1,479 | 1,148 | |
Equipment Financing Payments | ||||||
4 | 9 | 12 | 2 | 0 | - | |
Net Cash Provided by (Used in) Financing Activities | ||||||
3,920 | 11,304 | 10,671 | 3,498 | - | - | |
Payments of Grants Payable | ||||||
- | - | - | - | -32 | 0 | |
Net Cash Provided by Financing Activities | ||||||
- | - | - | - | 12,616 | 613 | |
Effect of Exchange Rate Changes on Cash | ||||||
5 | 7 | 4 | 6 | 90 | 3 | |
Net Decrease in Cash | ||||||
-4,227 | 198 | 4,170 | -4,733 | 8,227 | -334 | |
Supplemental Disclosures of Noncash Operating and Financing Activities | ||||||
Creation of Right-of-Use Assets and Related Lease Liabilities | ||||||
109 | - | - | - | - | - | |
Conversion of Non-Controlling Interests to Common Stock | ||||||
- | - | - | - | 6,818 | 0 | |
Creation of Right-of-Use Assets and Related Lease Liabilities | ||||||
- | 80 | 9 | 2,776 | 36,408 | 0 | |
Cancellation of Restricted Stock | ||||||
0 | - | - | - | - | - | |
Exercise of Common Warrants | ||||||
- | - | - | - | 0 | 0 | |
Conversion of Promissory Notes and Accrued Interest into Common Stock | ||||||
- | - | - | - | 3,532 | 0 | |
Deemed Dividend on Conversion of Preferred Stock | ||||||
- | - | - | - | 8,222 | 0 | |
Application of Deferred Offering Costs on IPO | ||||||
- | - | - | - | 1,148 | 0 | |
Warrant Liability Reclassified to Stockholders Equity | ||||||
- | - | - | - | 79 | 0 | |
Issuance of Common Stock to Acquire Jade Therapeutics, Inc. | ||||||
- | - | - | 2,909 | 0 | - | |
Contingent Liability in Connection with Jade Acquisition | ||||||
- | - | - | 1,210 | 0 | - | |
Property and Equipment Acquired Under Capital Lease | ||||||
- | - | - | 31 | 0 | - | |
Warrants issued to related parties in conjunction with issuance of amended convertible notes | ||||||
- | - | - | - | - | 1,398 | |
Settlement of a liability with shares | ||||||
- | - | - | - | - | 105 | |
Accrued interest added to notes | ||||||
- | - | - | - | - | 127 | |
ASU 2016-02 | ||||||
Creation of Right-of-Use Assets and Related Lease Liabilities | ||||||
136 | - | - | - | - | - | |